Impact Therapeutics-B's stock surged 15.59% intraday, staging a significant rebound in the Hong Kong market.

The movement represents a recovery following several sessions of profit-taking pressure since the company's highly anticipated IPO debut on May 13. The public offering was oversubscribed by 2,282 times, and shares had retreated more than 15% from their post-listing high before today's upward move, suggesting capital is flowing back into the stock after the recent correction.

Impact Therapeutics is a commercial-stage biotech company focused on precision anti-cancer therapies. Its core product, senaparib, a PARP1/2 inhibitor, received approval in China for first-line maintenance treatment of ovarian cancer in January and was included in the National Medical Insurance Directory in December, with reimbursed pricing effective since January.